Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Raymond James Initiates Coverage On Tvardi Therapeutics with Outperform Rating, Announces Price Target of $62

Author: Benzinga Newsdesk | July 14, 2025 10:50am
Raymond James analyst Ryan Deschner initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and announces Price Target of $62.

Posted In: TVRD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist